HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) 060103.Supplemental Data All Versions of this Article: clinchem.2005.060103v1 52/6/1196    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Persoon, A. C.M. Articles by van den Ouweland, J. M.W. Search for Related Content PubMed PubMed Citation Articles by Persoon, A. C.M. Articles by van den Ouweland, J. M.W. Related Collections Cancer Diagnostics (since 2002)

Thyroglobulin (Tg) Recovery Testing with Quantitative Tg Antibody Measurement for Determining Interference in Serum Tg Assays in Differentiated Thyroid Carcinoma

¹ Department of Endocrinology, University Medical Centre Groningen, Groningen, The Netherlands;² Nichols Institute Diagnostics, Bad Vilbel, Germany;³ Canisius-Wilhelmina Medical Centre, Department of Clinical Chemistry, Nijmegen, The Netherlands;

^aaddress correspondence to this author at: Canisius-Wilhelmina Medical Centre, Department of Clinical Chemistry, Weg door Jonkerbos 100, 6500 GS Nijmegen, The Netherlands; fax 31-24-3658671, e-mail j.v.d.ouweland{at}cwz.nl

Abstract

Background: Thyroglobulin (Tg) measurements are complicated by interference from Tg autoantibodies (TgAbs) or heterophilic antibodies (HAMAs). We used a new automated immunochemiluminometric assay (ICMA) with Tg recovery (TgR) on the Nichols Advantage® platform to reassess the clinical utility of recovery testing in detecting interference in serum Tg measurement in patients with differentiated thyroid carcinoma.

Methods: We used 2 TgAb methods to detect Tg measurement interference with TgR and quantitative TgAb measurement in sera from 127 patients. In a limited number of samples, we used an RIA as comparison method because it appeared to be minimally affected by TgAb.

Results: Prevalence of TgAbs was 13% (17 of 127) in either 1 or both TgAb assays. A compromised TgR (<70%) corresponded with TgAb positivity in either TgAb assay for 10 of 11 samples (91%), whereas a normal TgR (70%) corresponded with TgAb negativity in both assays for 95 of 101 samples (94%). In 6 TgAb-positive sera with TgR within the reference interval, there were no discrepancies between RIA and ICMA results. We obtained discordant RIA and ICMA results for 6 of 9 TgAb-positive sera with decreased TgR. In 1 TgAb-negative sample, the Tg result was falsely increased because of interference by HAMAs, as shown by an overrecovery of 126%.

Conclusions: The Nichols Advantage TgR assay is a valuable complementary method to overcome the technical problem of interference by TgAbs or HAMAs in TgAb assays. Further studies are needed to confirm the potential added value of this TgR assay.

The following articles in journals at HighWire Press have cited this article:

				P M Clark Laboratory services for thyroglobulin and implications for monitoring of differentiated thyroid cancer J. Clin. Pathol., May 1, 2009; 62(5): 402 - 406. [Abstract] [Full Text] [PDF]

				Y. Gao, H. Lu, Z. Yuan, and R. Zhu Tumor Markers in Thyroid Carcinoma With Pulmonary Metastases After Thyroidectomy Lab Med, January 1, 2009; 40(1): 30 - 34. [Abstract] [Full Text] [PDF]

eLetters: